Two-year prognosis of multinodular goiter following radiofrequency ablation based on all nodule burdens
Authors' conclusion
RFA provides cosmetic and symptomatic relief for an average of two years. RFA is an useful minimally invasive treatment modality for selected MNG patients.
Study context
- Population
- Multinodular goiter (MNG) patients with 2–5 benign nodules, >50% normal tissue on US, 1–3 well-defined benign dominant nodules on cytology, largest diameter ≥20 mm and/or clinical complaints, refusing or unable to undergo surgery
- Participants
- 185 patients
- Outcome
- Nodule burden after RFA
- Follow-up
- Mean 22.38±13.75 months (range, 12-60 months)
Methodological detailssingle-session radiofrequency ablation (RFA)
- Single-session RFA
Main finding
As reported in the abstract
Initial ablation ratio of target nodules at 1 month
100%
VRR of ablated nodules at 24 months, without regrowth
98.25%
Progressive disease (PD)
9.7%
18/185
Retreatment rate
2.2%
4/185
Observational data: associations, not effects.
Further findings
Cosmetic and symptomatic scores · after 48 months
- Cosmetic score decreased to
- 1
- Symptomatic score decreased to
- 0
Safety
- Complication rate
- 2.7% (5/185)
Original publication
Two-year prognosis of multinodular goiter following radiofrequency ablation based on all nodule burdens. Eur Thyroid J. Published 19 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →